资源整合与专业赋能，益普生与上药控股达成战略合作

Core Insights - The strategic partnership between Ipsen and Shanghai Pharmaceuticals aims to enhance resource integration and channel coverage for the drug Daparelix in the Chinese market, benefiting patients [1][2] - Ipsen's commitment to improving drug accessibility and patient welfare is highlighted as a significant milestone in their operations in China [1] - Shanghai Pharmaceuticals emphasizes the synergy created by combining Ipsen's brand influence with its extensive distribution network and academic promotion capabilities [1][2] Company Overview - Ipsen has been operating in the Chinese market for over 30 years, focusing on introducing high-quality products [1] - Shanghai Pharmaceuticals leads in the pharmaceutical health service sector, leveraging technological innovation and digitalization for development [2] - The CSO team of Shanghai Pharmaceuticals has nearly 10 years of industry experience, establishing a nationwide service network [2] Product Focus - Daparelix is a commonly used gonadotropin-releasing hormone analog (GnRHa) applied in various medical conditions, including prostate cancer and endometriosis [1] - The collaboration aims to deepen the product's market penetration and enhance the availability of quality healthcare services [2]